Enasidenib in Acute Myeloid Leukemia: Clinical Development and Perspectives on Treatment

Cancer Management and Research - New Zealand
doi 10.2147/cmar.s162784
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

Advances in Treatment Formulations for Acute Myeloid Leukemia

Drug Discovery Today
Drug DiscoveryPharmacology
2018English

Treatment of Childhood Acute Myeloid Leukemia in Bulgaria

Folia Medica
Medicine
2018English

Treatment of Older Adults With Acute Myeloid Leukemia: State of the Art and Current Perspectives

Haematologica
Hematology
2008English

Acute Myeloid Leukemia

JAMA - Journal of the American Medical Association
Medicine
2010English

Molecular Emergence of Acute Myeloid Leukemia During Treatment for Acute Lymphoblastic Leukemia

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2001English

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

FOXM1 Contributes to Treatment Failure in Acute Myeloid Leukemia

JCI insight
Medicine
2018English

FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2011English

Enasidenib, an Inhibitor of Mutant IDH2 Proteins, Induces Durable Remissions in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy